ArticleClinical and experimental nephrology2017
Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Article in Clinical and experimental nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Current status and research hotspots of pediatric nephrotic syndrome: a bibliometric analysis (2011-2025).Frontiers in pediatrics · 2026Pooled it
- Efficacy and safety of scheduled rituximab in children with refractory nephrotic syndrome after multi-target therapy failure.Pediatric nephrology (Berlin, Germany) · 2026Article
- Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome.Clinical and experimental nephrology · 2025Article
- Clinical practice guidelines for rituximab treatment in children with steroid-sensitive nephrotic syndrome.World journal of pediatrics : WJP · 2025Review
- Early relapse during B lymphocyte depletion of children with frequently relapse /steroid dependent nephrotic syndrome after rituximab treatment.BMC nephrology · 2025Article
- Risk factors and retreatment for relapse in childhood primary nephrotic syndrome treated with rituximab.Pediatric nephrology (Berlin, Germany) · 2025Article
- Article
- Long Term Evaluations of First Single-dose Rituximab in Children with Steroid-Dependent Minimal-Change Nephrotic Syndrome.Renal failure · 2024Observational
- Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab.Clinical and experimental nephrology · 2024Article
- Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2024Article
- Prediction Model and Decision Analysis for Early Recognition of SDNS/FRNS in Children.Journal of inflammation research · 2024Article
- Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.Clinical and experimental nephrology · 2023Article
- Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.Journal of the American Society of Nephrology : JASN · 2022Article
- The Curative Effect of Shuangshen Decoction Combined with Immunological Preparations in the Treatment of Pediatric Nephrotic Syndrome and Its Influence on the Rate of Complicated Infection and Recurrence.Computational and mathematical methods in medicine · 2022Article
- Use of rituximab in paediatric nephrology.Archives of disease in childhood · 2021Review
- Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen.Pediatric nephrology (Berlin, Germany) · 2021Review
- Clinical characteristics of patients with early relapse during B-cell depletion after rituximab treatment for complicated steroid-dependent nephrotic syndrome.Clinical and experimental nephrology · 2021Article
- Prophylactic rituximab administration in children with complicated nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2021Article
- Should rituximab be administered before cyclophosphamide as a first-line steroid-sparing agent to young children with steroid-dependent nephrotic syndrome?Clinical and experimental nephrology · 2020Article
- Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with complicated steroid-dependent nephrotic syndrome (SDNS), rituximab (RTX) followed by immunosuppressive agent (IS) can maintain remission without the use of prednisolone (PSL). However, available data on the predictive factors for relapse and the long-term outcome after this protocol are few.
methodsWe retrospectively analyzed 43 SDNS patients who were followed-up for a long time (>2 years, mean 5.4 years) after a single dose of RTX (375 mg/m
resultsThirty-nine patients (91 %) could discontinue PSL without relapses at a median of 154 days after the initial RTX. The first relapse of NS occurred in 39 patients (91 %) at a median of 586 days; additional RTX doses were administered in 28 patients (65 %). Kaplan-Meier analysis showed that shorter CD19 cell depletion (<150 days) and younger age at RTX initiation (<12.5 years) were significantly associated with high risk for first relapse after RTX (log rank p < 0.05). In multivariate analysis, mycophenolate mofetil therapy as maintenance IS after RTX was the only predicted risk factor for first relapse (hazard ratio 2.75; p = 0.027). At the last follow-up, IS was still used in 33 patients (77 %); treatment-free remission (>12 months) was achieved in only five patients (12 %).
conclusionsThe introduction of RTX may not be necessarily associated with improved long-term outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.